×

Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.

REVIEW FOR HEARTBURN DRUG NARROWED TO TWO

McCann, Merkley Newman Said to Be Finalists for Prevacid

By Published on .

NEW YORK (AdAge.com) -- TAP Pharmaceutical has narrowed the review for its heartburn drug Prevacid to two agencies, according to people familiar with the matter.

The two finalists are Interpublic Group of Cos.' McCann-Erickson Worldwide, New York, which is pitching with sibling Gillespie Healthcare, Princeton, N.J., and Omnicom Group's Merkley Newman Harty, New York.

Incumbent is Gillespie
Gillespie is the incumbent

Related Stories:
HEARTBURN DRUG PREVACID GOES INTO REVIEW
Pharmaceutical Marketer Eyes 'New Direction'
on the account. Prior to Gillespie, the account was at Cordiant Communications Group's Bates USA, New York.

A spokeswoman for TAP would only say a decision has not been made.

The account generated $37 million in spending in 2001, according to Taylor Nelson Sofres' CMR.

TAP is based in Lake Forest, Ill., and is a joint venture between Abbott Laboratories and Takeda Chemical Industries.

Most Popular